Dane Leone
Stock Analyst at Raymond James
(1.28)
# 3,636
Out of 5,182 analysts
69
Total ratings
33.96%
Success rate
-2.02%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $13.03 | +45.82% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $84 → $56 | $7.88 | +610.66% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $8.69 | +417.84% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $144.83 | -79.29% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $731.77 | +29.82% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.77 | +369.31% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $69.71 | -34.01% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $28.43 | +142.70% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $1.84 | +334.78% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $9.32 | +50.21% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $12.15 | +377.37% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $14.87 | +370.75% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.19 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $60.69 | +3.81% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $58.26 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.58 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $62.09 | +4.69% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $339.57 | -24.91% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $3.77 | +748.81% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $227.79 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $13.03
Upside: +45.82%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $84 → $56
Current: $7.88
Upside: +610.66%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $8.69
Upside: +417.84%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $144.83
Upside: -79.29%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $731.77
Upside: +29.82%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.77
Upside: +369.31%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $69.71
Upside: -34.01%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $28.43
Upside: +142.70%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $1.84
Upside: +334.78%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $9.32
Upside: +50.21%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $12.15
Upside: +377.37%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $14.87
Upside: +370.75%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.19
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $60.69
Upside: +3.81%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $58.26
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.58
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $62.09
Upside: +4.69%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $339.57
Upside: -24.91%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $3.77
Upside: +748.81%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $227.79
Upside: -